ResVita Bio

ResVita Bio is #hiring! Bring your passion for synthetic biology to our diverse team at ResVita Bio! We are developing exciting new treatments for the hundreds of millions of people suffering with destructive skin diseases.

? Happy New Year!! ?? As we welcome 2025, I’m thrilled to share that?San Francisco Business Times reporter?Ron Leuty?featured ResVita Bio. The article showcases our journey from an idea developed with my cofounder Jay Keasling to creating a platform technology for treating serious skin diseases like Netherton syndrome (NS) and atopic dermatitis (AD) through continuous protein therapy. 2024 was a pivotal year for ResVita Bio and following a very productive FDA INTERACT meeting, we are now nearing the submission of our FDA Pre-IND meeting as we prepare for our first clinical trials in 2026. Most importantly, our preclinical results for NS have been extraordinary, validating our approach to delivering continuous, localized protein therapy safely and effectively. Our work isn’t just about innovation—it’s about creating hope for patients and families who currently have few or no options. We’re poised to make 2025 an even greater year of breakthroughs and milestones. Wishing everyone a happy, healthy, and successful New Year! ???#ResVitaBio?#Dermatology?#RareDiseases #ContinuousProteinTherapy #BiotechInnovation #NewYear2025

?? Regulatory Milestone Achieved! ?? We’re excited to share that ResVita Bio had a productive FDA INTERACT meeting for RVB-003, our investigational therapy for Netherton Syndrome. The FDA's valuable feedback on biocontainment, CMC, and preclinical studies aligns with our innovative continuous protein therapy platform, bringing us closer to our Pre-IND submission in 2025. This milestone reinforces our commitment to transforming the treatment of skin diseases and improving patient outcomes with sustained therapeutic protein delivery directly to the skin. Thank you to our team, partners, and supporters for making this progress possible! ?? #Biotech #SkinDisease #NethertonSyndrome #FDA #Regulatory #Innovation #ContinuousProteinTherapy

?? Exciting News! ?? We're thrilled to announce that the NIH has awarded ResVita Bio a $2.03M Phase II grant to advance RVB-003, our breakthrough treatment for Netherton Syndrome! This is a huge step forward for continuous protein therapy, a revolutionary approach that enables sustained therapeutic protein production directly on the skin—offering unparalleled safety and efficacy for treating skin diseases. This brings us one step closer to transforming the lives of patients suffering from this devastating condition. Stay tuned for more updates as we move closer to clinical development!